UK-based Redx Pharma said it expects to start first-in-man studies with RXC006 during 2020 as the first pre-clinical data of the drug candidate has suggested that the compound has great potential as a fibrosis treatment.
Cyxone said that T20K, its investigational drug for the treatment of multiple sclerosis (MS), has succeeded in a preclinical program by yielding positive results in the toxicology studies.
Scientists at The Wistar Institute and collaborators have engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models.
Inovio Pharmaceuticals said that it has completed animal testing of DNA-encoded monoclonal antibodies targeting the immune checkpoint molecule CTLA-4.
Scientists in the UK claim to have identified a crucial molecular player in a subtype of lung cancer that could pave way for a new approach towards treating the condition.
Scientists in the UK believe that patients with sudden liver failure could benefit from a new treatment in the future that could cut down the need for transplants by preventing a process called senescence with certain anti-cancer therapy drugs.
Oxford BioMedica has collaborated with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Imperial Innovations for the development of a long-term therapy to treat patients with cystic fibrosis.
Kalytera Therapeutics has announced the termination of its pre-clinical development programs in the treatment of bone disease to focus its resources on graft versus host disease (GVHD) and pain programs.
Biopharmaceutical firm Onxeo has announced encouraging results from a series of preclinical studies evaluating Livatag interest for pancreatic cancer.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.